Results 211 to 220 of about 45,095 (259)

Dosimetric characterization of scatter foil-enhanced contact collimation for small superficial electron beam therapy. [PDF]

J Appl Clin Med Phys
Alhussan A, Crilly R.
europepmc   +1 more source

Minimally Invasive Facial Lifting Using the Versatility of Calcium Hydroxyapatite (STIIM). [PDF]

J Cosmet Dermatol
Saavedra Deus B, Viana R.
europepmc   +1 more source

Salvage Interstitial Brachytherapy for Isolated Local Recurrence of Cervical and Endometrial Cancer: A Retrospective Analysis Stratified by Type of Pelvic Irradiation History. [PDF]

Cancers (Basel)
Fujioka D, Saito T, Sumiya T, Baba K, Murakami M, Numajiri H, Itagaki H, Shikama A, Tenjimbayashi Y, Akiyama A, Nakao S, Mizumoto M, Nakai K, Satoh T, Sakurai H.   +14 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

D90: The Strongest Contributor to Setting Time in Mineral Trioxide Aggregate and Portland Cement

Journal of Endodontics, 2015
The setting times of commercial mineral trioxide aggregate (MTA) and Portland cements vary. It was hypothesized that much of this variation was caused by differences in particle size distribution.Two gram samples from 11 MTA-type cements were analyzed by laser diffraction to determine their particle size distributions characterized by their percentile ...
William N. Ha, Dale P. Bentz, Bill Kahler, Laurence J. Walsh   +3 more
openaire   +4 more sources

Point A vs. HR-CTV D90 in MRI-based cervical brachytherapy of small and large lesions

Brachytherapy, 2016
To evaluate the dosimetric benefits of MRI-based brachytherapy in small and large high-risk clinical target volume (HR-CTV) in cervical cancer.Twenty-eight fractions obtained from sixteen cervical cancer patients treated with MRI-based high-dose-rate brachytherapy with standard tandem and ovoid applicators were used; original fractions were optimized ...
Grant Harmon, Abbie Diak, Steven M. Shea, Joseph H. Yacoub, William Small, Matthew M. Harkenrider   +5 more
openaire   +3 more sources

125I Monotherapy Using D90 Implant Doses of 180 Gy or Greater

International Journal of Radiation Oncology*Biology*Physics, 2008
The purpose of this study was to characterize the oncologic results and toxicity profile of patients treated with (125)I implants using the dose delivered to 90% of the gland from the dose-volume histogram (D90) of greater than 144 Gy.From June 1995 to Feb 2005, a total of 643 patients were treated with (125)I monotherapy for T1-T2 prostate cancer with
Johnny, Kao, Nelson N, Stone, Amir, Lavaf, Vishruta, Dumane, Jamie A, Cesaretti, Richard G, Stock   +5 more
openaire   +3 more sources

Whole prostate D90 and V100: A dose–response analysis of 2000 consecutive 125I monotherapy patients

Brachytherapy, 2014
To examine the relationship between whole prostate dose metrics and disease-free survival (DFS) after (125)I low-dose-rate prostate brachytherapy (LDR-PB).Data for the first 2000 LDR-PB monotherapy implants were extracted from a database containing patient, tumor, dosimetric, and outcomes information.
W James, Morris, Ingrid, Spadinger, Mira, Keyes, Jeremy, Hamm, Michael, McKenzie, Tom, Pickles   +5 more
openaire   +3 more sources

The correlation between D90 and outcome for I-125 seed implant monotherapy for localised prostate cancer

Radiotherapy and Oncology, 2006
In 1998 Stock and Stone demonstrated a dose response relationship correlating D90 with probability of biochemical control and showed that a D90 of 140 Gy is a highly significant factor in predicting PSA relapse free survival (PSA-RFS). Although, a mean D90 of over 140 Gy was achieved in our series, there is nevertheless a normal distribution with 20 ...
Dan, Ash, Bashar, Al-Qaisieh, David, Bottomley, Brendan, Carey, Joji, Joseph   +4 more
openaire   +3 more sources

NDV‐D90 inhibits 17β‐estradiol‐mediated resistance to apoptosis by differentially modulating classic and nonclassic estrogen receptors in breast cancer cells

Journal of Cellular Biochemistry, 2020
AbstractNewcastle disease virus (NDV) is endowed with the oncolytic ability to kill tumor cells, while rarely causing side effects in normal cells. Both estrogen receptor α (ERα) and the G protein estrogen receptor (GPER) modulate multiple biological activities in response to estrogen, including apoptosis in breast cancer (BC) cells.
Peng Shan, Bo Tang, Shanshan Xie, Zengling Zhang, Jiehou Fan, Zheng Wei, Chun Song   +6 more
openaire   +3 more sources

Dosimetric Quantifiers for Low Dose Rate Prostate Brachytherapy: V100 Is Superior to D90

International Journal of Radiation Oncology*Biology*Physics, 2005
M.A. Papagikos, A.F. deGuzman, P.J. Rossi, D.L. McCullough, P.E. Clark, W.R. Lee   +5 more
openaire   +2 more sources